Print
24 May 2014
RIA Novosti
MOSCOW, May 22 (RIA Novosti) - Russian Prime Minister Dmitry Medvedev has charged the Ministries of Health, Industry, Economic Development and Finance, in conjunction with development institutions, with submitting proposals to the government for public funding of measures to support the development of nuclear medicine and biomedical technologies in 2015-2017, according to a statement on the website of the Cabinet.
The departments received these instructions following the meeting of the Presidential Council for Economic Modernization and Innovative Development. The proposals, providing support for the development and manufacture of cell and tissue products, genomic technologies and development of innovation infrastructure, including that on the basis of pilot innovative biomedical clusters, are to be offered for the government’s consideration until October 7.
In addition, Prime Minister has instructed Ministry of Industry, Ministry of Economic Development, Ministry of Finance and Ministry of Health to submit until October 6 the draft regulation on the order of extension of public contracts for drug design, including taking into account the timing necessary to receive permits to conduct clinical tests.
Several ministries, including Federal Customs Service and Federal Tax Service are to submit proposals to the government until August 21 for the exempt from VAT and its refund for importing raw materials and components for the production of medical devices into Russia.
Ministry of Industry, Ministry of Health, Ministry of Finance and Ministry of Economic Development are to submit proposals until September 3 for inclusion of activities aimed at development and organization of production of pharmaceutical substances into the Federal Target Program "Development of the Pharmaceutical and Medical Industries of the Russian Federation for the period up to 2020 and Beyond", as well as suggestions for inclusion of measures for the development and localization of components of medical devices into the state program "Development of Electronics and Radio Electronics industry in 2013-2025."
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.